Quick Answer
Black Diamond Therapeutics, Inc. reported Operating Income of $12.52 million for fiscal year 2025.
Black Diamond Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $12.52M | +115.9% |
| 2024 | -$78.78M | +8.9% |
| 2023 | -$86.46M | +6.9% |
| 2022 | -$92.83M | +26.8% |
| 2021 | -$126.87M | -82.4% |
| 2020 | -$69.57M | -137.2% |
| 2019 | -$29.33M | -229.4% |
| 2018 | -$8.90M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.98M | +39.4% | +18.2% |
| June 30, 2025 | -$13.42M | +39.4% | -124.6% |
| March 31, 2025 | $54.53M | +369.3% | +400.8% |
| September 30, 2024 | -$18.13M | +24.5% | +18.1% |
| June 30, 2024 | -$22.13M | -10.5% | -9.3% |
| March 31, 2024 | -$20.25M | +6.1% | +15.7% |
| September 30, 2023 | -$24.01M | -8.5% | -19.9% |
| June 30, 2023 | -$20.03M | +13.6% | +7.1% |
- Black Diamond Therapeutics, Inc. showed an increase of +115.9% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Black Diamond Therapeutics, Inc.’s operating income has grown by 240.6% (from -$8.90 million to $12.52 million).
- The most recent figure is from Black Diamond Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: